Microbial Iron Chelators: A Possible Adjuncts for Therapeutic Treatment of SARS-CoV-۲ like Viruses

There is a need for targeted, effective antiviral therapeutic treatment for the global threat of COVID-۱۹, like viral pandemics. Our efforts in this direction present the in-silico testing of a hypothesis through molecular docking. We have demonstrated the possibility of a microbial siderophore desferrioxamine-E produced by Pseudomonas stutzeri SGM-۱ for effective drug targeting and drug development against SARS-CoV-۲, like viruses. Iron homeostasis and COVID-۱۹ have a close relationship. An iron chelator desferrioxamine-E binding with the SARS-CoV-۲ virus can inhibit the viral RNA binding and packaging into the new virions inside the host cell. The well-known efficacy of iron chelation and RNA binding domain of SARS-CoV-۲ nucleocapsid interaction of desferrioxamine-E studied through molecular docking has promising potential for exploring microbial iron chelators as adjuncts for in-silico clinical trials and randomized clinical trials.

کلیدواژه ها:

Iron chelator ، Siderophore ، Desferrioxamine E ، SARS-CoV-۲ ، Molecular docking